<SEC-DOCUMENT>0001829126-25-000098.txt : 20250107
<SEC-HEADER>0001829126-25-000098.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107164859
ACCESSION NUMBER:		0001829126-25-000098
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250107
DATE AS OF CHANGE:		20250107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zeo ScientifiX, Inc.
		CENTRAL INDEX KEY:			0001557376
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474180540
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87575
		FILM NUMBER:		25515466

	BUSINESS ADDRESS:	
		STREET 1:		3321 COLLEGE AVENUE
		STREET 2:		SUITE 246
		CITY:			DAVIE
		STATE:			FL
		ZIP:			33314
		BUSINESS PHONE:		888-963-7881

	MAIL ADDRESS:	
		STREET 1:		3321 COLLEGE AVENUE
		STREET 2:		SUITE 246
		CITY:			DAVIE
		STATE:			FL
		ZIP:			33314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Organicell Regenerative Medicine, Inc.
		DATE OF NAME CHANGE:	20180625

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biotech Products Services & Research, Inc.
		DATE OF NAME CHANGE:	20150917

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BESPOKE TRICYCLES INC
		DATE OF NAME CHANGE:	20120831

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Skycrest Holdings, LLC
		CENTRAL INDEX KEY:			0001952164
		ORGANIZATION NAME:           	
		IRS NUMBER:				980594973

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		1930 HARRISON STREET
		STREET 2:		SUITE 206
		CITY:			HOLLYWOOD
		STATE:			FL
		ZIP:			33020
		BUSINESS PHONE:		954-701-4123

	MAIL ADDRESS:	
		STREET 1:		1930 HARRISON STREET
		STREET 2:		SUITE 206
		CITY:			HOLLYWOOD
		STATE:			FL
		ZIP:			33020
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001829126-22-020607</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Skycrest Holdings, LLC -->
          <cik>0001952164</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $0.001 Par Value</securitiesClassTitle>
      <dateOfEvent>12/30/2024</dateOfEvent>
      <previouslyFiledFlag>true</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001557376</issuerCIK>
        <issuerCUSIP>68621D206</issuerCUSIP>
        <issuerName>Zeo Scientifix, Inc.</issuerName>
        <address>
          <com:street1>3321 COLLEGE AVENUE</com:street1>
          <com:street2>SUITE 246</com:street2>
          <com:city>DAVIE</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33314</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ian T. Bothwell</personName>
          <personPhoneNum>888-963-7881</personPhoneNum>
          <personAddress>
            <com:street1>3321 COLLEGE AVENUE</com:street1>
            <com:street2>SUITE 246</com:street2>
            <com:city>DAVIE</com:city>
            <com:stateOrCountry>FL</com:stateOrCountry>
            <com:zipCode>33314</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001952164</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Skycrest Holdings, LLC</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>FL</citizenshipOrOrganization>
        <soleVotingPower>302167.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>302167.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>302167.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.59</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>The number of shares Beneficially Owned by the Reporting Person consists of 302,167 shares of common stock of the Issuer held by the Reporting Person representing 4.59% of the voting power based on 6,582,419 shares of common stock outstanding as of September 13, 2024, as reported by the Issuer in its July 31, 2024 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 16, 2024.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Shares of Common Stock $0.001 Par Value and Series C Preferred Stock $0.001 Par Value</securityTitle>
        <issuerName>Zeo Scientifix, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>3321 COLLEGE AVENUE</com:street1>
          <com:street2>SUITE 246</com:street2>
          <com:city>DAVIE</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33314</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 2 to the Statement on Schedule 13D ("Amendment No. 2") filed with the Securities and Exchange Commission (the "SEC") on August 16, 2018 (the "Schedule 13D"), on behalf of Skycrest Holdings, LLC (the "Reporting Person"), with respect to the common stock of Zeo ScientifiX, Inc. (the "Issuer"), is being filed pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to amend and supplement certain information set forth below in the items indicated. All capitalized terms used in this Amendment No. 2 and not otherwise defined herein have the meanings ascribed to such terms in the Schedule 13D and or Amendment No. 1 filed with the SEC on February 14, 2023. Except as amended and supplemented herein, the Schedule 13D, including the definitions of capitalized terms not otherwise defined herein, remains in full force and effect.</commentText>
      </item1>
      <item2>
        <filingPersonName>This Amendment No. 2 is being filed by the Reporting Person;</filingPersonName>
        <principalBusinessAddress>The Reporting Person's business address is 1930 Harrison Street, Suite 204, Hollywood, Florida 33020;</principalBusinessAddress>
        <principalJob>Not applicable.</principalJob>
        <hasBeenConvicted>The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors);</hasBeenConvicted>
        <convictionDescription>The Reporting Person was not, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws; and</convictionDescription>
        <citizenship>Not applicable.</citizenship>
      </item2>
      <item3>
        <fundsSource>The additional shares of the Issuer's common stock held by the Reporting Person as reported in Item 5(c) of and elsewhere in this Amendment No. 2 were open market purchases funded by the Reporting Person's working capital.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The additional shares of the Issuer's common stock acquired by the Reporting Person as reported in Item 5(c) of and elsewhere in this Amendment No. 2, were open market purchases funded by the Reporting Person's working capital. The Reporting Person has no definite plan to acquire or dispose of additional shares of the Issuer's common stock in open market or private transactions, but may do so in the future, subject to compliance with the Exchange Act and the rules and regulations thereunder.

Except as set forth in the preceding paragraph, the Reporting Person has no plans or proposals which relate to or would result in:

(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

(b) Any additional extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

(c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;

(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e) Any material change in the present capitalization or dividend policy of the issuer;

(f) Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

(g) Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j) Any action similar to any of those enumerated above.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>As of the filing date of this Amendment No. 2, the Reporting Person beneficially owns 302,167 shares of the common stock of the Issuer, representing 4.59% of the class;</percentageOfClassSecurities>
        <numberOfShares>The Reporting Person has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of all of the 302,167 shares; and</numberOfShares>
        <transactionDesc>The Reporting Person has effected the following transactions in the class of securities reported on (the Issuer's common stock and Series C Preferred Stock) during the past sixty days:

Date   Nature of the Transaction    Number of Shares   Price

11/18/2024   Purchase Common Stock  10,000  $2.59
11/19/2024   Purchase Common Stock  5,000    $2.65
11/20/2024   Purchase Common Stock  7,289    $2.75
11/20/2024   Purchase Common Stock  500       $2.95
11/22/2024   Purchase Common Stock  10,508  $4.00
12/11/2024   Purchase Common Stock  266       $3.02
12/20/2024   Gift of Warrants to Purchase Common Stock  (750,000)  $0.00
12/26/2024   Gift of Warrants to Purchase Common Stock  (350,000)  $0.00
12/30/2024   Gift of Series C Preferred Stock   (50)  $0.00</transactionDesc>
        <listOfShareholders>None.</listOfShareholders>
        <date5PercentOwnership>The Reporting Person ceased to be the beneficial owner of 50 shares of Series C Preferred Stock on December 30, 2024.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>There are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>None.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Skycrest Holdings, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Louis Birdman</signature>
          <title>Louis Birdman, Manager</title>
          <date>01/07/2025</date>
        </signatureDetails>
      </signaturePerson>
      <commentText>The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.</commentText>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
